Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

A 56-year-old man with severe aortic stenosis underwent transapical TAVR in 2012. In 2017, the patient was referred for exertion dyspnea and transesophageal echocardiogram showed severe stenosis of the bioprosthesis...

An elective right coronary artery PCI was scheduled in an 83-year-old gentleman. Due to the presence of severely diffuse and calcified disease, rotational atherectomy was decided, but the burr got entrapped in the severely calcified and tortuous proximal segment of the artery...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Sponsorship by Industry Partners is evolving into an indirect scheme. Find out what this means for Healthcare Professionals.

Coronary obstruction is a major concern in patients undergoing TAVI for degenerated bioprostheses (valve-in-valve [ViV]) and is associated with a 30-day mortality rate of around 50%.1 While several transcatheter techniques to lacerate bioprosthetic valve leaflets prior to TAVI placement (such as BASILICA) have been described, they are...

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

On the occasion of World Hypertension Day, Felix Mahfoud speaks about the value of renal denervation, including the latest data and what we can learn about renal denervation at EuroPCR 2022.

Reported from ACC 2023 / WCC

Edoardo Zancanaro provides his take on this clinical trial presented by Enoch Akowuah at the American College of Cardiology Scientific Session (ACC.23/WCC).

Alex Sticchi & Jonathan Curio provide their take on the clinical trial presented by Gregg W. Stone at the American College of Cardiology Scientific Sessions (ACC.23/WCC).

Mirvat Alasnag provides her take on the TEER Shock study which was presented at TCT 2022 by Mohamad A. Alkhouli.

What’s the safest approach when surgical options are off the table? This real-life case shows how complex coronary revascularsation and TAVI were performed in a single session, supported by Impella.

Explore the rationale behind the sequence, the device choices, and the outcome in a high-risk patient with...

Alex Sticchi provides his take on the iCABG trial presented by Rasa Ordiene at TCT 2025, in San Francisco.

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

An 84-year-old man with arterial hypertension and previous hepatocellular carcinoma was admitted to our Emergency Department for new onset of exertional angina (CCS 3). The patient had a history of three-vessel coronary artery disease treated by complete surgical revascularization in 2007...

The authors present a case of PCI for left main trunk bifurcation divided by a flap-like structure in a 67-year-old man suffering from effort angina, in which they successfully used a novel tracking technique by modifying the reverse controlled antegrade and retrograde tracking (CART), which they called...

The European Bifurcation Club Left Main (EBC MAIN) trial addressed the issue of provisional single stent versus upfront double stenting in 467 patients with true bifurcation distal left main disease. 

So far, only one other randomized trial, DKCRUSH-V (n=482), has addressed the same research question, showing better...

Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.

The manuscript for this trial has not been published and all assumptions are based upon the presentation.

Watch this EuroIntervention image to learn how the collision of a TAV device during valve crossing in ViV TAVI can potentially cause instability or dehiscence of the sutureless bioprosthesis, contributing to severe poorly tolerated PVL.